ylliX - Online Advertising Network
Company Ticker News

Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp. The Regeneron Analyst: Analyst Michael King initiated coverage of Regeneron shares with a Buy rating and a $703 price target.

...read full article on Benzinga

ylliX - Online Advertising Network